The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst)
 
Yan Lin
No Relationships to Disclose
 
Joseph J. Drabick
Consulting or Advisory Role - Castle Biosciences
 
Rogerio Izar Neves
No Relationships to Disclose
 
Marc S. Ernstoff
Stock and Other Ownership Interests - GE Healthcare
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; Lion Biotechnologies; Omniseq
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst)
 
Igor Puzanov
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Merck
 
Priyanka Vallabhaneni
No Relationships to Disclose
 
James F. Pingpank
No Relationships to Disclose
 
Matthew Peter Holtzman
No Relationships to Disclose
 
Cindy Sander
No Relationships to Disclose
 
John M. Kirkwood
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Merck; Novartis
Research Funding - Merck (Inst); Prometheus (Inst)